BioStem Technologies, Inc. (BSEM)
1.49
+0.01
(+0.68%)
USD |
NASDAQ |
Oct 28, 12:23
BioStem Technologies Enterprise Value : 20.64M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 20.64M |
| October 26, 2026 | 21.71M |
| October 23, 2026 | 22.24M |
| October 22, 2026 | 23.84M |
| October 21, 2026 | 24.20M |
| October 20, 2026 | 23.49M |
| October 19, 2026 | 21.71M |
| October 16, 2026 | 31.51M |
| October 15, 2026 | 30.62M |
| October 14, 2026 | 31.86M |
| October 13, 2026 | 34.36M |
| October 12, 2026 | 37.75M |
| October 09, 2026 | 38.28M |
| October 08, 2026 | 41.31M |
| October 07, 2026 | 36.85M |
| October 06, 2026 | 38.28M |
| October 05, 2026 | 43.36M |
| October 02, 2026 | 42.91M |
| October 01, 2026 | 48.97M |
| September 30, 2026 | 49.33M |
| September 29, 2026 | 62.52M |
| September 28, 2026 | 66.44M |
| September 25, 2026 | 68.04M |
| September 24, 2026 | 63.41M |
| September 23, 2026 | 61.98M |
| Date | Value |
|---|---|
| September 22, 2026 | 65.19M |
| September 21, 2026 | 72.68M |
| September 18, 2026 | 78.74M |
| September 17, 2026 | 71.96M |
| September 16, 2026 | 66.97M |
| September 15, 2026 | 65.73M |
| September 14, 2026 | 69.29M |
| September 11, 2026 | 71.07M |
| September 10, 2026 | 68.67M |
| September 09, 2026 | 69.29M |
| September 08, 2026 | 65.55M |
| September 04, 2026 | 60.38M |
| September 03, 2026 | 58.60M |
| September 02, 2026 | 57.35M |
| September 01, 2026 | 56.64M |
| August 31, 2026 | 59.84M |
| August 28, 2026 | 57.17M |
| August 27, 2026 | 62.87M |
| August 26, 2026 | 59.49M |
| August 25, 2026 | 62.16M |
| August 24, 2026 | 64.12M |
| August 21, 2026 | 57.35M |
| August 20, 2026 | 59.84M |
| August 19, 2026 | 53.87M |
| August 18, 2026 | 50.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -51.36M |
| CorMedix, Inc. | 509.14M |
| Eloxx Pharmaceuticals, Inc. | -8.120M |
| Breakthrough Chemistry, Inc. | 0.241M |
| Cardiac Biotech Solutions, Inc. | 5.690M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.971M |
| Revenue (Quarterly) | 7.899M |
| Total Expenses (Quarterly) | 16.87M |
| EPS Diluted (Quarterly) | -0.5178 |
| Gross Profit Margin (Quarterly) | 52.55% |
| Profit Margin (Quarterly) | -113.6% |
| Earnings Yield | -112.6% |
| Normalized Earnings Yield | -112.64 |